Biotechnology company running clinical operations to research, develop and deliver psychedelics medicines to treat mental conditions and addictions Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) announced having acquired the exclusive rights to the data from phase 2a Bristol Imperial MDMA in Alcoholism Study (BIMA) conducted by Imperial College London.
Imperial College London is ranked among the leading psychedelics centers around the world. BIMA was an open label safety research aiming at finding out the role of MDMA-assisted psychotherapy in treating patients suffering from alcohol use disorder (AUD).
Results from the study were published back in February and they indicated that MDMA has a great potential to be more effective in treating AUD. The study showed a 20% relapse rate within the first nine months which is a significant decline compared to the 75% relapse rate with traditional treatments.
Awakn says this data will help it advance forward by enabling the company to come up with a better design and more efficient execution of its clinical program.
“Drinking behavior outcomes from the BIMA phase 2a study that Awakn just acquired indicates that MDMA has the potential to be more effective at treating AUD, with only a 20% relapse rate within the first nine months. This compares very favorably with the current best available traditional treatments for patients’ post-detox with AUD,” said Awakn’s chief medical officer, Dr. Ben Sessa.
